Curcumin Reverses the Scopolomine-induced Cognitive Impairment by iNOS and Acetylcholinesterase Inhibition in Rodent Model of Schizophrenia
Abstract
Schizophrenia is a severe neuro-developmental psychiatric disorder. Curcumin is a polyphenolic compound extracted from turmeric. It is known for its antioxidant, anti-inflammatory, neuroprotective, and precognitive properties. The purpose of the current study was to evaluate the role of curcumin in scopolamine induced cognitive impairment in animal model of schizophrenia. The elevated plus-maze test was utilised to study the curcumin effect on learning and memory. Curcumin (100 mg/kg, i.p.) was administered daily for 28 days in animals. Behavioural tests such as transfer latency (TL) and spontaneous alteration behaviour was assessed after the last dose of curcumin on the 28th day, followed by biochemical estimations. Present study reported that curcumin showed anti-amnesic effect in animal models of cognitive impairment of schizophrenia. Curcumin reduced the TL compared to toxic control group (scopolamine per se) (P <0.001) in elevated plus maze. In spontaneous alteration behaviour test, curcumin significantly increased percentage alteration and possible alteration as compared to toxic control group (P <0.001). A significant change in acetyl cholinesterase activity, nitrate and oxidative parameters was observed, thus, confirming its anti acetyl cholinesterase, NOS (nitric oxide synthase) inhibition and antioxidant properties (P <0.05). The present study put forward the claim of curcumin as a new and safer therapeutic alternative for the treatment of cognitive impairment in Schizophrenia. The underlying mechanism of this potential effect may be related to anticholinesterase and nitric oxide synthase inhibition activity of curcumin. Further research is warranted for confirming the suggested pathways accountable for memory alleviating effects of curcumin in Schizophrenia.
Keywords:
Acetylcholinesterase, Cognition, Curcumin, iNOS inhibition, SchizophreniaDOI
https://doi.org/10.25004/IJPSDR.2020.120205References
Liu C, Everall I, Pantelis C, Bousman C. Interrogating the evolutionary paradox of schizophrenia: A novel framework and evidence supporting recent negative selection of schizophrenia risk alleles. Frontiers in genetics. 2019;10:389.
Freedman R. Schizophrenia. N Engl J Med. 2003; 349: 1738–1749.
Hill SK, Reilly JL, Keefe RS, Gold JM, Bishop JR, Gershon ES, Tamminga CA, Pearlson GD, Keshavan MS, Sweeney JA. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry. 2013; 170(11):1275-84.
Eum S, Hill SK, Rubin LH, Carnahan RM, Reilly JL, Ivleva EI, Keedy SK, Tamminga CA, Pearlson GD, Clementz BA, Gershon ES, Keshavan MS, Keefe RSE, Sweeney JA, Bishop JR. Cognitive burden of anticholinergic medications in psychotic disorders. Schizophr Res. 2017; 190:129-135.
Baitz HA, Thornton AE, Procyshyn RM, Smith GN, MacEwan GW, Kopala LC, Barr AM, Lang DJ, Honer WG. Antipsychotic medications: linking receptor antagonism to neuropsychological functioning in first episode psychosis. J Int Neuropsychol Soc. 2012; 18:717–727.
Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesisof schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012; 37(1):4-15.
Tani M, Akashi N, Hori K, Konishi K, Kitajima Y, Tomioka H, Inamoto A, Hirata A, Tomita A, Koganemaru T, Takahashi A, Hachisu M. Anticholinergic Activity and Schizophrenia. Neurodegener Dis. 2015; 15(3):168-74.
Prast H, Philippu A. Nitric oxide as modulator of neuronal function. Progr Neurobiol. 2001; 64: 51–68.
Bernstein HG, Bogerts B, Keilhoff G. The many faces of nitric oxide in schizophrenia. A review. Schizophr Res. 2005; 78: 69–86.
Salvioli S, Sikora E, Cooper EL, Franceschi C. Curcumin in cell death processes: a challenge for CAM of age-related pathologies. Evidence-Based Complementary and Alternative Medicine. 2007; 4(2):181-90.
Fujisawa S, Atsumi T, Ishihara M, Kadoma Y. Cytotoxicity, ROS-generation activity and radical-scavenging activity of curcumin and related compounds. Anticancer research. 2004; 24(2B):563-70.
Rao MN. Nitric oxide scavenging by curcuminoids. Journal of pharmacy and pharmacology. 1997; 49(1):105-7.
Butterfield DA, Castegna A, Pocernich CB, Drake J, Scapagnini G, Calabrese V. Nutritional approaches to combat oxidative stress in Alzheimer’s disease. The Journal of nutritional biochemistry. 2002; 13(8):444-61.
Jung KK, Lee HS, Cho JY, Shin WC, Rhee MH, Kim TG, Kang JH, Kim SH, Hong S, Kang SY. Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide-activated primary microglia. Life sciences. 2006; 79(21):2022-31.
Gilhotra N, Dhingra D. GABAergic and nitriergic modulation by curcumin for its antianxiety-like activity in mice. Brain research. 2010; 1352:167-75.
Akinyemi AJ, Oboh G, Fadaka AO, Olatunji BP, Akomolafe S. Curcumin administration suppress acetylcholinesterase gene expression in cadmium treated rats. Neurotoxicology. 2017; 62:75-79.
Abbasi MA, Ilyas M, Sonia A, Shahwar D, Raza MA, Khan KM, Ashraf M, Afzal I, Ambreen N. Curcumin and its derivatives: Moderate inhibitors of acetylcholinesterase, butyrylcholinesterase and trypsin. Scientia Iranica. 2012; 19(6):1580-3.
Miyazaki S, Imaizumi M, Onodera K. Ameliorating effects of histidine on scopolamine-induced learning deficits using an elevated plus-maze test in mice. Life sciences. 1995; 56(19):1563-70.
Ragozzino ME, Pal SN, Unick K, Stefani MR, Gold PE. Modulation of hippocampal acetylcholine release and spontaneous alternation scores by intrahippocampal glucose injections. Journal of neuroscience. 1998; 18(4):1595-601.
Ellman GL, Courtney KD, Andres Jr V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical pharmacology. 1961; 7(2):88-95.
Classics Lowry O, Rosebrough N, Farr A, Randall R. Protein measurement with the Folin phenol reagent. J biol Chem. 1951; 193:265-75.
Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-arginine/nitric oxide area of research. Journal of Chromatography B. 2007; 851(1-2):51-70.
Hall CN, Attwell D. Assessing the physiological concentration and targets of nitric oxide in brain tissue. The Journal of physiology. 2008; 586(15):3597-615.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical biochemistry. 1979; 95(2):351-8.
Ellman GL. Tissue sulfhydryl groups. Archives of biochemistry and biophysics. 1959; 82(1):70-7.
Claiborne AL. Catalase activity. CRC handbook of methods for oxygen radical research. 1985; 1:283-4.
Golechha M, Bhatia J, Arya DS. Studies on effects of Emblica officinalis (Amla) on oxidative stress and cholinergic function in scopolamine induced amnesia in mice. J Environ Biol. 2012; 33:95‑100.
Alikatte KL, Akondi BR, Yerragunta VG, Veerareddy PR, Palle S. Antiamnesic activity of Syzygium cumini against scopolamine induced spatial memory impairments in rats. Brain Dev. 2012; 34:844‑51.
SoukhakLari R, Moezi L, Pirsalami F, Ashjazadeh N, Moosavi M. Curcumin ameliorates scopolamine-induced mice memory retrieval deficit and restores hippocampal p-Akt and p-GSK-3β. European journal of pharmacology. 2018; 841:28-32.
Barak S, Weiner I. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology. 2007; 32(5):989-99.
Fanaei H, Khayat S, Kasaeian A, Javadimehr M. Effect of curcumin on serum brain-derived neurotrophic factor levels in women with premenstrual syndrome: A randomized, double-blind, placebo-controlled trial. Neuropeptides. 2016; 56:25-31.
Paul V, Ekambaram P. Involvement of nitric oxide in learning & memory processes. Indian J Med Res. 2011; 133:471-8.
Khan RA, Najmi AK, Khuroo AH, Goswami D, Akhtar M. Ameliorating effects of thymoquinone in rodent models of schizophrenia. African Journal of Pharmacy and Pharmacology. 2014; 8(15):413-21.
Boultadakis A, Pitsikas N. Effects of the nitric oxide synthase inhibitor L-NAME on recognition and spatial memory deficits produced by different NMDA receptor antagonists in the rat. Neuropsychopharmacology. 2010; 35(12):2357.
Rezayof A, Amini R, Rassouli Y, Zarrindast MR. Influence of nitric oxide on morphine-induced amnesia and interactions with dopaminergic receptor agents. Physiol. Behav. 2006; 88(1-2):124-131.
Göteborg University. "New Discoveries About Nitric Oxide Can Provide Drugs For Schizophrenia." ScienceDaily. ScienceDaily, 23 November 2007. www.sciencedaily.com/releases/2007/11/071121213845.htm
Dong S, Zeng Q, Mitchell ES, Xiu J, Duan Y, Li C, Tiwari JK, Hu Y, Cao X, Zhao Z. Curcumin enhances neurogenesis and cognition in aged rats: implications for transcriptional interactions related to growth and synaptic plasticity. PLoS One. 2012; 7(2):e31211.
Chimakurthy J, Talasila M. Effects of curcumin on pentylenetetrazole-induced anxiety-like behaviors and associated changes in cognition and monoamine levels. Psychology & Neuroscience. 2010; 3(2):239.
Rajasekar N, Dwivedi S, Tota SK, Kamat PK, Hanif K, Nath C, Shukla R. Neuroprotective effect of curcumin on okadaic acid induced memory impairment in mice. Eur J Pharmacol. 2013; 715(1-3):381-94.
Tiwari V, Chopra K. Attenuation of oxidative stress, neuroinflammation, and apoptosis by curcumin prevents cognitive deficits in rats postnatally exposed to ethanol. Psychopharmacology (Berl). 2012; 224(4):519-35.
Rainey-Smith SR, Brown BM, Sohrabi HR, et al. Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults. Br J Nutr. 2016; 115:2106–2113.
Cox KH, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol. 2015; 29: 642–651.
Sarraf P, Parohan M, Javanbakht MH, Ranji-Burachaloo S, Djalali M. Short-term curcumin supplementation enhances serum brain-derived neurotrophic factor in adult men and women: A systematic review and dose–response meta-analysis of randomized controlled trials. Nutrition Research. 2019 May 9.
Kucukgoncu S, Guloksuz S, Tek C. Effects of Curcumin on Cognitive Functioning and Inflammatory State in Schizophrenia: A Double-Blind, Placebo-Controlled Pilot Trial. Journal of clinical psychopharmacology. 2019; 39(2):182-4.
Wynn JK, Green MF, Hellemann G, et al. The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: a randomized controlled study. Schizophr Res. 2017; 195:572–573.
Woodbury-FarinaM, Cernovsky Z, Chiu S, et al. Proof of concept of randomized controlled study of Curcumin C-3 Complex as adjunct treatment in schizophrenia: effects on negative and depressive symptoms. Ontario, Canada: Presented at Natural Bioactives Conference, July 9–12; 2012.
Published
Abstract Display: 819 
PDF Downloads: 412 
